IARTINTEGRA LIFESCIENCES HOLDINGS CORP
Surgical & Medical Instruments & Apparatus
- Revenue
- $1.6B
- 1.5% YoY
- Operating margin
- -30.2%
- 1810% YoY
- EBITDA
- −$449M
- 733% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $445M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear17% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.6B | $1.5B | $1.6B | $1.6B | 1.5% |
| Operating income | $197M | $239M | $112M | $28M | −$493M | 1837% |
| Net income | $169M | $181M | $68M | −$7M | −$517M | 7390% |
| Operating cash flow | $312M | $264M | $140M | $129M | $50M | 61% |
| Capex | $48M | $42M | $67M | $104M | $81M | 22% |
| Stock-based comp | $36M | $28M | $20M | $24M | $19M | 24% |
| Buybacks | $0 | $125M | $275M | $52M | $221K | 100% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 19 | 123 |
| FY2024 | — | — | 39 | 138 |
| FY2023 | — | — | 75 | 138 |
| FY2022 | — | — | 96 | 134 |
| FY2021 | — | — | 115 | 145 |